X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (55120) 55120
Book Review (12345) 12345
Publication (4785) 4785
Newsletter (3089) 3089
Newspaper Article (2396) 2396
Book Chapter (435) 435
Conference Proceeding (180) 180
Magazine Article (160) 160
Transcript (145) 145
Trade Publication Article (121) 121
Book / eBook (99) 99
Dissertation (61) 61
Web Resource (21) 21
Report (18) 18
Government Document (14) 14
Data Set (11) 11
Reference (7) 7
Paper (5) 5
Presentation (2) 2
Streaming Video (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (46006) 46006
humans (45169) 45169
male (23631) 23631
female (22727) 22727
adult (18768) 18768
middle aged (18161) 18161
hepatitis (17467) 17467
antiviral agents - therapeutic use (14293) 14293
gastroenterology & hepatology (14202) 14202
hepatitis c (13770) 13770
hepatitis c virus (12207) 12207
health aspects (10060) 10060
hepatitis c, chronic - drug therapy (8684) 8684
infection (8652) 8652
treatment outcome (8597) 8597
aged (8485) 8485
interferon (8245) 8245
hepatitis b (8018) 8018
infectious diseases (7780) 7780
liver (7222) 7222
virology (7173) 7173
hepacivirus - genetics (6879) 6879
infections (6513) 6513
genotype (6383) 6383
therapy (6203) 6203
risk factors (6200) 6200
interferon-alpha - therapeutic use (6191) 6191
drug therapy, combination (6060) 6060
antiviral agents (5733) 5733
care and treatment (5603) 5603
research (5544) 5544
animals (5490) 5490
hepatitis b virus (5435) 5435
analysis (5432) 5432
hiv (5369) 5369
drug therapy (5155) 5155
immunology (5128) 5128
virus diseases (5117) 5117
ribavirin (5009) 5009
viruses (4959) 4959
hepatitis c - drug therapy (4940) 4940
viral load (4801) 4801
virus-infection (4793) 4793
ribavirin - therapeutic use (4717) 4717
adolescent (4606) 4606
liver diseases (4582) 4582
hepatitis b, chronic - drug therapy (4562) 4562
abridged index medicus (4349) 4349
prevalence (4199) 4199
pharmacology & pharmacy (4088) 4088
human immunodeficiency virus--hiv (4021) 4021
retrospective studies (3884) 3884
cirrhosis (3862) 3862
antiviral agents - administration & dosage (3783) 3783
young adult (3783) 3783
hepatitis b virus - genetics (3778) 3778
medical research (3776) 3776
hepacivirus - drug effects (3772) 3772
recombinant proteins (3761) 3761
hepatocellular-carcinoma (3672) 3672
patients (3634) 3634
hcv (3561) 3561
antiviral agents - pharmacology (3507) 3507
hepatitis c, chronic - virology (3503) 3503
disease (3372) 3372
liver cirrhosis (3322) 3322
medicine (3223) 3223
biological response modifiers (3221) 3221
gastroenterology and hepatology (3220) 3220
hepatitis-c virus (3120) 3120
antiviral agents - adverse effects (3098) 3098
transplantation (3076) 3076
genetic aspects (3064) 3064
hepatology (3053) 3053
microbiology (3022) 3022
lamivudine (3021) 3021
time factors (2997) 2997
rna, viral - blood (2954) 2954
hepatitis c, chronic - complications (2938) 2938
medicine, experimental (2923) 2923
epidemiology (2906) 2906
digestive system diseases (2884) 2884
rna (2879) 2879
hiv infections - complications (2877) 2877
hepatitis c - virology (2874) 2874
hepatitis c - complications (2853) 2853
research article (2842) 2842
liver cancer (2839) 2839
medicine & public health (2809) 2809
mortality (2786) 2786
medicine, general & internal (2770) 2770
polyethylene glycols - therapeutic use (2726) 2726
liver - pathology (2660) 2660
virus (2649) 2649
hepatocellular carcinoma (2639) 2639
human-immunodeficiency-virus (2637) 2637
proteins (2611) 2611
liver transplantation (2530) 2530
hiv infections - drug therapy (2525) 2525
replication (2518) 2518
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (62) 62
Online Resources - Online (8) 8
Collection Dvlpm't (Acquisitions) - Closed Orders (5) 5
Collection Dvlpm't (Acquisitions) - Vendor file (4) 4
UofT at Mississauga - Stacks (2) 2
Dentistry (Harry R Abbott) - May be requested in 6-10 wks (1) 1
Scarborough Hospital - Online (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Patient Education (1) 1
UTL at Downsview - May be requested (1) 1
Women's College Hospital - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (58907) 58907
Chinese (461) 461
French (394) 394
Russian (325) 325
German (305) 305
Spanish (297) 297
Japanese (237) 237
Polish (150) 150
Italian (99) 99
Korean (99) 99
Hungarian (69) 69
Croatian (33) 33
Portuguese (29) 29
Czech (26) 26
Dutch (23) 23
Turkish (23) 23
Serbian (16) 16
Ukrainian (16) 16
Danish (14) 14
Romanian (12) 12
Hebrew (7) 7
Slovak (7) 7
Norwegian (6) 6
Swedish (6) 6
Finnish (4) 4
Bosnian (3) 3
Bulgarian (3) 3
Albanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Hepatology, ISSN 0270-9139, 10/2006, Volume 44, Issue 4, pp. 896 - 906
Journal Article
Journal Article
Blood, ISSN 0006-4971, 11/2012, Volume 120, Issue 20, pp. 4150 - 4159
Posttransplantation human herpesvirus-8 (HHV8)/Kaposi sarcoma herpesvirus (KSHV) primary infection and/or reactivations are associated with uncommon and... 
SOLID-ORGAN TRANSPLANTATION | PRIMARY-EFFUSION LYMPHOMA | RENAL-TRANSPLANT | BONE-MARROW-TRANSPLANTATION | SARCOMA-ASSOCIATED HERPESVIRUS | PREVIOUS HUMAN-HERPESVIRUS-8 INFECTION | MULTICENTRIC CASTLEMAN-DISEASE | VISCERAL KAPOSIS-SARCOMA | STEM-CELL TRANSPLANTATION | HEMATOLOGY | EPSTEIN-BARR-VIRUS | Lymphohistiocytosis, Hemophagocytic - etiology | Postoperative Complications - etiology | Castleman Disease - drug therapy | Herpesviridae Infections - etiology | Humans | Immunosuppressive Agents - therapeutic use | DNA, Viral - analysis | Transplants - virology | Sarcoma, Kaposi - drug therapy | Herpesvirus 8, Human - isolation & purification | Postoperative Complications - virology | Herpesvirus 8, Human - pathogenicity | Hepatitis, Viral, Human - virology | Castleman Disease - virology | Postoperative Complications - drug therapy | Virus Activation | Hepatitis, Viral, Human - etiology | Lymphoproliferative Disorders - etiology | Herpesviridae Infections - transmission | Antibodies, Monoclonal, Humanized - therapeutic use | Antiviral Agents - therapeutic use | Lymphohistiocytosis, Hemophagocytic - drug therapy | Lymphoproliferative Disorders - virology | Rituximab | Castleman Disease - etiology | Sarcoma, Kaposi - etiology | Sarcoma, Kaposi - virology | Herpesviridae Infections - virology | Forecasting | Herpesviridae Infections - drug therapy | Lymphohistiocytosis, Hemophagocytic - virology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Transplantation - adverse effects | Lymphoproliferative Disorders - drug therapy | Disease Management | Anthracyclines - therapeutic use | Immunocompromised Host | Hepatitis, Viral, Human - drug therapy | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Herpesviridae Infections - epidemiology | Index Medicus | Abridged Index Medicus
Journal Article
1999, Methods in Molecular Medicine, ISBN 0896035611, Volume 24., xiiv, 404 p. ill.
In Antiviral Methods and Protocols, experienced scientists describe-in an easily-followed format-their state-of-the-art techniques for evaluating antiviral... 
Antiviral agents -- Laboratory manuals | Laboratory manuals | Antiviral agents | Anti-infective agents | Infectious Diseases | Emerging infectious diseases | Medicine & Public Health
Book
HIV Medicine, ISSN 1464-2662, 11/2009, Volume 10, Issue 10, pp. 591 - 613
Journal Article
Gut, ISSN 0017-5749, 04/2018, Volume 67, Issue 4, pp. 595 - 598
Most deaths from viral hepatitis are due to hepatitis B and hepatitis C. Globally, an estimated 257million people were living with HBV and 71million people... 
anti-viral therapy | Hepatitis B immunization | Hepatitis B virus | Hepatitis C virus | hepatocellular carcinoma | E-ANTIGEN | SUBSEQUENT RISK | INCREASED RISK | TAIWAN | LIVER-DISEASES | CIRRHOSIS | B-VIRUS DNA | INFECTION | LEVEL | NATURAL-HISTORY | GASTROENTEROLOGY & HEPATOLOGY | Liver Neoplasms - prevention & control | Liver Neoplasms - virology | Smoking - adverse effects | Hepatitis B e Antigens | Antiviral Agents - therapeutic use | Carcinoma, Hepatocellular - prevention & control | Humans | Risk Factors | Hepatitis C, Chronic - prevention & control | Carcinoma, Hepatocellular - virology | Hepatitis C, Chronic - complications | Evidence-Based Medicine | Hepatitis B Surface Antigens | Alcohol Drinking - adverse effects | Hepatitis B, Chronic - prevention & control | Hepatitis, Viral, Human - prevention & control | Hepatitis B, Chronic - complications | Hepatitis, Viral, Human - complications | DNA, Viral | Hepatitis, Viral, Human - drug therapy | Syngeneic grafts | Chronic infection | Alcohol | Viruses | Infections | Family medical history | Blood | Cofactors | Antioxidants | Liver cancer | Hepatitis | Allografts | Hepatology | Natural history | Deoxyribonucleic acid--DNA | Cholangiocarcinoma | Antigens | Enzymes | Immunization | Liver diseases | Hepatitis B surface antigen | Drinking behavior | Diabetes mellitus | a-fetoprotein | Cigarette smoking | Ribonucleic acid--RNA | Lymphoma | Vitamins | Studies | Hepatitis B e antigen | Cirrhosis | Androgens | Tuberculosis | Womens health | Biomarkers | Tumor suppressor genes | Interferon | Hepatitis C | Hepatitis B | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10029, pp. 1703 - 1704
  The only indicator for hepatitis that is being considered by the Inter-Agency and Expert Group on Sustainable Development Goal Indicators is "new hepatitis B... 
Internal Medicine | Hepatitis, Viral, Human - prevention & control | Disease Eradication | World Health Organization | Antiviral Agents - therapeutic use | Humans | United Nations | Health Priorities | Hepatitis, Viral, Human - drug therapy | Viral Hepatitis Vaccines - therapeutic use | Hepatitis, Viral | Medical colleges |